




# African Journal of Biological Sciences



## HERBALISM IN ALZHEIMER DISEASE: A FUTURISTIC APPROACH IN MANAGEMENT OF NEURODEGENERATIVE AILMENTS

Dev Sharan Chaturvedi <sup>1\*</sup> Ramteke Kuldeep Hemraj <sup>1</sup> Dharmendra Singh Rajput <sup>1</sup> Naveen  
Gupta<sup>1</sup>

Patel College of Pharmacy, Madhyanchal Professional University, Bhopal-462044 M.P.India

Corresponding Author : Dev Sharan Chaturvedi <sup>1\*</sup> (Ph.D. Research Scholar )

Email: [chaturvedidev44@gmail.com](mailto:chaturvedidev44@gmail.com)

Mob No- 91-8103164578

ORCID ID : <https://orcid.org/0009-0007-4220-1790>

### ABSTRACT

A growing number of people suffer from a variety of diseases that is referred to as neurodegenerative diseases of the brain. Some of these are caused by an infection, like HIV/AIDS, while others are caused by a person's age (like Alzheimer's and Parkinson's disease). Alzheimer's disease (AD) is a complex, multifaceted mental illness characterized by age-dependent memory loss and cognitive impairment in multiple domains. It is the most common type of dementia among people who are getting older because there is a significant loss of cholinergic neurons in a particular area of the brain. In traditional Ayurvedic and Chinese medicine, many plants have been used to treat cognitive impairments, including neurodegenerative diseases like Alzheimer's. New medications, including those for cognitive issues, have been discovered through an ethnopharmacological approach based on plants. Due to their potential to be as effective as psychiatric medications, herbal treatments that have demonstrated anti-alzheimer effects should receive more attention in future research. This article looks at a lot of plants and the active ingredients in them that have been used in traditional Ayurvedic treatments to improve cognitive function or fight aging.

**Keywords:** Alzheimer's disease; neurodegeneration; cognitive impairment; clinical trial; herbal medicine

Article History

Volume 6, Issue 13, 2024


Received: 18 June 2024

Accepted: 02 July 2024

doi:10.48047/AFJBS.6.13.2024.773-789

## 1 Introduction


Worldwide, Alzheimer's disease (Promotion) is referred to as a pandemic. With moderate synaptic damage and neuronal degeneration, it is one of the prevalent forms of dementia [1]. Both have to do with perception, which is weaker in people who are promoted. Promotion is influenced by the connections between age, education, inherited characteristics, and environmental factors. Amyloid plaques, neurofibrillary tangles, provocative cycles, and aggravation of synapses are some of the obsessive features identified in the central nervous system (CNS) in Promotion [Figure 1]. There is no distinction at all between inconsistent Promotion and familial Promotion [2]. Obsessive changes are a last resort in patients with irregular promotion as opposed to patients with familial promotion. Advertisement pathogenesis is aided by strange digestion of amyloid precursor protein (Application), as demonstrated by research using promotional minds and mouse models [3].



**Figure 1: Demonstration of normal and Alzheimer Brain**

The early phase of Advancement, the autosomal dominating gained structure, is a fast development sort of disease with more restricted perseverance time stood out from the conflicting design. Patients typically have a family history marked by promotion and are frequently associated with inherited factors. As a highly polygenic disease, irregular promotion has a slow progression, with a predominant rate of > 95% in all cases [4]. It occurs as a result of the extracellular accumulation of the 42-amino acid corrosive peptide known as amyloid-beta (A) plaque, which is associated with an Application cleavage defect or lack of (A) leeway. In addition, the 4 isoform of Apolipoprotein E (Apo E4) is an additional


important hereditary risk factor for irregular promotions(**Figure 2**). Through the movement of neprilysin (NEP) and insulin-degrading catalyst (IDE), Apo E4 inhibits A's proteolytic debasement. Multifunctional influences have introduced them as a medicinal procedure for the treatment of numerous contaminations. We have concentrated on a few restorative spices that are appropriate for the treatment of Promotion in this review [5].



**Figure 2: Mechanism of Alzheimer disease and different neurological conditions**

## 2. Etiology of AD

The etiology of AD is elaborated below in detail(**Figure 3**)



**Figure 3: Etiology of Alzheimer disease (AD)**

### 2.1 Amyloid-beta plaque

One of the most important histopathological signs of promotion is extracellular plaque aggregation. It is frequently made in the brain and is important for cell flagging and synaptic pliancy. An excessive amount of (A) fibrils causes neurotoxicity, synaptotoxicity, cell death, neurodegeneration, and ultimately neuronal death. In addition, it has been demonstrated that a number of corrupting chemicals, such as metalloendopeptidase, NEP, and IDE, can control (A)[6].

### 2.2 Neurofibrillary preposition

Another essential neuropathological sign of promotion are neurofibrillary tangles. They are made by hyperphosphorylating the protein called tau protein, which is related to the microtubules in the cytoskeleton [7]. It has been discovered that A boosts tau phosphorylation and promotes NFT development. The progression of NFT is linked to difficulties in daily life, mental decline, and neurodegeneration, particularly in Promotion [8].

### 2.3 Deviation in neurotransmission

Glutamatergic framework Glutamate is the primary excitatory synapse in the brain and is linked to a variety of synaptic versatility components, which is necessary for encoding

learning and memory specifics. Through NMDA receptors, impaired AMPK eliminates synaptic versatility. Apo E4 can possess the NMDA receptors and hinder synaptic versatility in Promotion in an A-free manner [9-10].

## 2.4 The Cholinergic System

Acetylcholine (ACh), which is found in a lot of neurotransmitters in the brain, is essential for mental control and memory formation. Individually, acetylcholinesterase and choline acetyltransferase compounds combine and corrupt it. ACh is reduced and the cholinergic framework is disrupted when Throb and BChE are overactive [11]. Additionally, clinical evidence demonstrates that Throb can improve (A) affidavit and production in Promotion patients. The vague cholinesterase catalyst BchE, also known as pseudocholinesterase, hydrolyzes a variety of choline esters. It is primarily associated with glial and endothelial cells in the brain, playing a minor role in regulating ACh levels in the mind [12].

## 3 Current Treatment Options

It is evident that there are no direct prescriptions to change neuronal and synaptic obliteration, and supported sedates only ease clinical side effects at the moment. Curiously, current research suggests the use of home-grown prescriptions, micronutrients, supplements, and manufactured drugs to alleviate Promotion side effects [13]. There were no restrictions on distribution or language. Search for expressions in Cross segment (clinical subject heading (Grid) with the words 'Alzheimer affliction, dementia, cognizance issues' was performed first. "Natural" and "Phytotherapy" were the watchwords for the following section (**Figure 4**). The Jadad's estimation scale was used to assess the hybrid effects of the two questions. Standards for incorporation: Each of the found articles was freely evaluated by three examiners [14]. The following methods were used to select the articles

- a) Randomization should be used in the investigations; twice blind and under control (with a comparison group and a treatment group).
- b) Studies should either be led simultaneously or outline strategic strategies in the hybrid.
- c) Due to its hybrid nature, it took roughly seven days to waste time.
- d) Patients who were included in the studies were divided into the following three grades:

### 5.1 *Lavandulaangustifolia*

*Lavandulaangustifolia*, or lavender, is a fragrant bush that belongs to the Lamiaceae family. In traditional treatments, this plant's various concentrates, such as rejuvenating balm, fluid concentrate, alcoholic concentrate, hydroalcoholic concentrate, and phenolic remove, have been used. Through searching for free radicals, it is demonstrated that the lavender watery concentrate has a significant anti-oxidant effect. The organization of a watery concentrate of lavender in the A-infused rodents restored the decayed pliancy of hippocampal glutamatergic synaptic transmission in terms of the degree of neuronal action [15]. In a similar vein, the hippocampal protein articulation in the hippocampus was altered by intracerebroventricular infusion of (A). The concentrate re-establishes the metabolic profile of Promotion provided creatures, as demonstrated by a metabolic analysis of serum obtained from the Promotion model of rodents receiving fluid concentrate of lavender. Due to the various constituents of oil-based, heavy drinker, and fluid concentrates of lavender, caution should be practiced when utilizing the natural medication, despite the fact that conduct, electrophysiological, and histological studies confirm the beneficial effect of lavender on the treatment of promotion. For instance, whereas the medicinal ointment of lavender advances the arrangement of (A) fibrils, the watery concentrate of lavender inhibits polymerization of the (A) monomer [16].

### 5.2 *Ginkgo biloba*

The ginkgo, or ginkgo, is a huge tree with long, erratic branches and a rakish crown. This well-known traditional Chinese helpful spice serves multiple purposes. It has been used for centuries in medicine to treat a variety of ailments [17]. The apoptotic pathway is another significant system implicated in various neurodegenerative diseases. *G. biloba* appears to be an enemy of apoptotic specialist due to its support of mitochondrial layer trustworthiness and restriction of cytochrome c delivery. It prevents the preapoptotic structures and associated caspase overflow from forming. Numerous studies have demonstrated that flavonoids—natural terpene lactone components of *ginkgo biloba*—and ginkgolide have distinct and potent anti-inflammatory effects by inhibiting platelet-initiating factor, a regulator of the combination of proinflammatory cytokines. Refined neurons demonstrate that *G. biloba* also protects neurons from hypoxia, H<sub>2</sub>O<sub>2</sub>, NO, glutamate-induced poisoning, and oxygen deprivation [18].

### 5.3 *Melissa officinalis*

The family Lamiaceae includes *Melissa officinalis*, which is also known as lemon ointment. During the summer, this plant produces tiny white blossoms and leaves that have a light lemon scent. In dementia patients, this phytomedicine is used to boost motivation and behavior. They attributed this mental activity's ability to inhibit Throb movement to its supporting effect. In Promotion patients, *M. officinalis* reduces neuronal agitation and treats mental brokenness [19]. Through a reduction in A-induced neurotoxicity, the restorative plant also exhibits neuroprotective effects. Together, the unique drug effects of *M. officinalis* against cholinesterase, cancer prevention, and neurotoxicity have made home-made medicine a strong contender for preventing side effects from neurodegenerative conditions like promotion [20].

### 5.4 *Crocus sativus*

*Crocus sativus*, also known as saffron, is a member of the *Iridaceae* family. It has been widely used in traditional medicine. This native plant is credited with calmness, extremist searching, and neuroprotective effects. Phenolic and carotenoids are the primary sources of saffron's movement as a cancer prevention agent [21]. *C. sativus* exhibits calming properties by concealing pro-inflammatory cytokines. It enhances the up-guideline for NEP chemicals and lipoprotein receptor-related protein 1. By making BBB less secure, it can increase (A) leeway. Saffron is found to play a significant role in the prevention of (A) plaque arrangement in Promotion by acting as an enemy of amyloidogenic movement and against (A)fibrilization[22].

### 5.5 *Panax ginseng*

The base of a plant in the *Panax* family that belongs to the *Araliaceae* family is *Panax ginseng*. It occupies a unique position in traditional medical treatment. This hand-picked flavor fills typically in mountains and contains triterpene glycosides (Ginsenosides), responsible for major pharmacological activities [23]. In addition, it reactivates choline acetyltransferase in a Promotion-themed creature model. In addition, it exhibits neuroprotective properties by suppressing Promotion's glutamate-induced harm. In vivo and in vitro tests have shown that ginseng calms the body by restricting the expression of inflammatory mediators like TNF, NF-B, IL1, and IL6. It also lowers the level of the chemical COX-2, which is a crucial intermediary in the fiery cycle [24].

### 5.6 *Salvia miltiorrhiza*

Another member of the Lamiaceae family, *Salvia miltiorrhiza* has slender stems and typically dispersed leaves. It has been extensively used to treat a variety of diseases [25]. In addition, a review demonstrated that tanshinone reestablishes scopolamine-induced learning and memory deficits. Tanshinone moves in a way that is harmful to apoptosis because of either the down-regulation of caspase-3 or the up-regulation of Bcl-2. Tanshinone has the ability to start the Bcl-xL pathway, which stops A-induced apoptosis [26].

### 5.7 *Magnolia officinalis*

*Magnolia officinalis* is a deciduous tree that produces fragrant blossoms that are used as a rich source of naturally dynamic mixtures. The bark of the tree is thick and has a sweet scent. This healing spice exhibits a number of therapeutic perspectives, including neuroprotective exercises, mitigating, and hostile to oxidative. Additionally, it inhibits H<sub>2</sub>O<sub>2</sub>-induced neurotoxicity and suppresses ROS age. Magnolol and honokiol stop Throb movement and energize ACh's arrival in the brain, particularly in the hippocampus. In a promotional animal model, it has been documented that the ethanol concentrate of *M. officinalis* prevents memory loss. According to the evidence, ethanol concentrate of this restorative spice reduces Hurt levels and movement in the cortex and hippocampus of scopolamine-treated mice [27].

### 5.8 *Shankhpushpi*

It is also known as *Convolvulus pluricaulis* (Cp) *Shankhpushpi*, also known as *Convolvulus pluricaulis* (Cp), is used to improve memory and recover nerves. Triterpenoids, flavonol glycosides, anthocyanins, and steroids are the major compound components responsible for Cp's nootropic and memory-enhancing properties. When compared to age-matched saline controls, rodents treated with Cp remove showed a significant increase in dendritic spreading focuses and processes. Despite the extensive research demonstrating Cp's beneficial properties in vitro and in vivo, the spice has not been evaluated clinically to determine whether it can prevent dementia [28].

### 5.9 *Turmeric (Curcuma longa)*

Turmeric is a flowering plant that belongs to the ginger family Zingiberaceae and is native to Southeast Asia and the Indian subcontinent. Curcuminoids, polyphenolic compounds, are primarily responsible for this rhizome plant's radiant yellow-orange variety. As a sedative, disinfectant, and antibacterial, turmeric has long been used to treat a wide range of

conditions, such as liver detoxification, preventing contamination and irritation, adjusting cholesterol levels, treating sensitivities, boosting processing, and supporting vulnerability [29]. In contrast to studies on animals, only a small number of clinical examinations have an effect on human mental functioning, and the results are not clear. Scientists are almost unanimous in their belief that curcumin's neuroprotective effects are enhanced when combined with other dietary supplements like piperine, -lipoic acid, N-acetylcysteine, B vitamins, L-ascorbic acid, and folate. As a result, improvements are required, and future research should focus on ways to improve curcumin's BBB porousness and fundamental bioavailability [30].


### **5.10 Ashwagandha (Withaniasomnifera)**

Ashwagandha, also known as winter cherry or Indian ginseng, is one of the most well-known spices that has been recommended as a mind-renewing supplement for promotion. It is suggested to increase energy, improve overall health, and act as a nerve tonic. Alkaloids and the phytoesterols sitosterols VII-X, beta-sitosterol, are additional components [31]. An Application/PS1 mouse model of promotion's oral administration of a semi-refined concentrate of ashwagandha prevented the collection of (A) peptides and switched conduct deficiencies. The liver low-thickness lipoprotein receptor-related protein intervened in this ashwagandha-induced restorative effect. Using an advertisement model of *Drosophila melanogaster*, researchers discovered that ashwagandha treatment reduced A's harmful effects and extended life span. In addition, the treatment group showed significant improvements in supported consideration, data handling speed, and leader capability [99]. These tests lend credence to Ashwagandha's ability to improve memory and leadership skills in people with SCI or MCI [32].

### **5.11 Brahmi (Bacopamonnieri)**

Brahmi, also known as Bacopamonnieri (Bm), is a long-lasting, restorative creeper plant that was discovered in the muddy, damp wetlands of Southern and Eastern India, Australia, Europe, Africa, Asia, and both North and South America. Bm is recommended as a treatment for mental stress, cognitive decline, epilepsy, sleep deprivation, and asthma in the Ayurvedic medication system [33]. The majority of studies that looked into the effects of Bm on people's mental development focused on typical, older people. The findings suggested that Bm could be used to treat memory impairment in people who were sufficiently old. Ten people were given 500 mg of Sideritis alone, 320 mg of Bm extricate, or a hybrid

combination. Sideritis separate has been shown to enhance comprehension in promotional animal models thanks to its abundance of various flavonoids. The Alzheimer's Illness Appraisal Scale-Mental Subscale (ADAS-machine gear-piece) and Clock-Drawing Test (CDT), both of which can assess the risk of MCI progression to promotion, were used to evaluate mental and memory aid performance. Examiners noted basic improvements in ADAS-pinion and CDT scores [34]. When compared to standard qualities, the observed sixty-day improvements in ADAS-pinion and CDT were measurably significant. Concentration and consideration, synapses, chemicals, trophic variables, cyclic AMP, particle channels, protein record, neural connection development, and supplements all have an impact on memory. Bm remove, either by itself or in combination with other mixtures, can be used to modify some of these cycles [35].



**Figure 4: Herbs and plants used in the management of Alzheimer disease**


### 6 Milestone in AD

The deliberate audit found that two natural definitions and two spices could be used to treat Promotion's mental aggravation: *Salvia officinalis*, *Melissa officinalis*, and Yi-Gan San and Ba Wei Di Huang Wan (BDW). *Ginkgo biloba* was as of late recognized in one metaanalysis, and simply the completions of the survey will be considered. The movement instruments of these flavors and subtleties are not prominent. Monoterpene glycosides, polyphenol flavonoids (including rosmarinic acid), and monoterpene aldehydes have been proposed as

the synthetic structures of the natural ointment of Melissa and Salvia leaf removes. In vitro, these components have a variety of perceptible effects, including a strong inhibitor of oxidative movement and a preference for the nicotinic and muscarinic receptors in the human cerebral cortex [36]. This last part is especially interesting because the regulation of cholinergic frameworks should play a role in improving mental capacity, especially in promotion. None of the studies looked at the rate of regulation or compared the dynamic rule to ongoing treatments with memantine or an ACE inhibitor [37].

## **7 Administration of herbs and drugs**

Avoiding the BBB, which prevents the participation of various expected medical professionals, is the most effective test for sedative conveyance into the brain(**Figure 5**). Although oral administration of the spices is a common method of administration, no reliable studies have been conducted to determine whether the native components approach the CNS from the fundamental circulation. Intranasal administration (INA) is painless, quick, avoids the BBB, and directly targets the CNS [38]. This approach has been used to treat cognitive decline in Promotion-transgenic mouse models. The role that the endothelial cells that cover the CNS vessels play in facilitating the passage of oil-derived solutes into the cerebrum and prefrontal cortex is the focus of ongoing research [39].



**Figure 5: Elaboration of different routes of administration of herbal drug against Alzheimer disease**

## 8. Conclusion & future Prospect

Alzheimer's disease affects approximately 5.8 million Americans. By 2050, it is anticipated that 13.8 million people will have Alzheimer's or other forms of dementia. Medical services and lost compensation for Promotion patients and guardians will cost an estimated USD 290 billion in the United States alone in 2019. Strategic restrictions like poor review configuration, typically small example sizes, poor result measures, and inappropriate end-point determinations are expected to be overcome through more in-depth research [40]. It is anticipated that the authentic data base of traditional medication frameworks, in conjunction with combinatorial sciences and high-throughput screening methods, will simplify the process by which natural terms and definitions can be used in the medication development cycle to provide new useful prompts promotion [41].

**REFERENCES**

1. Kalaria PN, Karad SC, Raval DK. A review on diverse heterocyclic compounds as the privileged scaffolds in antimalarial drug discovery. *European Journal of Medicinal Chemistry*. 2018;158:917-36.
2. Kalaria PN, Karad SC, Raval DK. A review on diverse heterocyclic compounds as the privileged scaffolds in antimalarial drug discovery. *European journal of medicinal chemistry*. 2018;158:917-36.
3. Baldisserotto A, Demurtas M, Lampronti I, Moi D, Balboni G, Vertuani S, et al. Benzofuranhydrazones as potential scaffold in the development of multifunctional drugs: Synthesis and evaluation of antioxidant, photoprotective and antiproliferative activity. *European journal of medicinal chemistry*. 2018; 156:118-25.
4. Mughal EU, Sadiq A, Ashraf J, Zafar MN, Sumrra SH, Tariq R, Mumtaz A, Javid A, Khan BA, Ali A, Javed CO. Flavonols and 4-thioflavonols as potential acetylcholinesterase and butyrylcholinesterase inhibitors: synthesis, structure-activity relationship and molecular docking studies. *Bioorg. Chem*. 2019; 91: 103124
5. Organization WH. (2021) Dementia. <https://www.who.int/news-room/fact-sheets/detail/dementia>. (Accessed 9 November 2021).
6. Stanciu GD, Luca A, Rusu RN., Bild V, BescheaChiriac SI, Solcan C, Bild W, Ababei, DC. Alzheimer's Disease pharmacotherapy in relation to cholinergic system involvement. *Biomolecules* . 2019 ;10 (1): 112-125.
7. Nguyen HD, Jo WH, Hoang NHM, Kim MS, Curcumin-attenuated TREM1/DAP12/NLRP3/caspase-1/IL1B, TLR4/NF- $\kappa$ B pathways, and Tau hyperphosphorylation induced by 1,2-diacetyl benzene: an in vitro and in silico study. *Neurotox. Res*. 2022; 40(5): 1272-1291.
8. Mughal EU, Javid A, Sadiq A, Murtaza S, Zafar MN, Khan BA, Sumrra SH, Tahir MN, Kanwal, Khan KM. Synthesis, structure-activity relationship and molecular docking studies of 3-Oflavonol glycosides as cholinesterase inhibitors. *Bioorg. Med. Chem*. 2018; 26 (12): 3696– 3706
9. Sekioka R, Honda S, Akashiba H, Yarimizu J, Mitani Y, Yamasaki S. Optimization and biological evaluation of imidazopyridine derivatives as a novel scaffold for c-

- secretase modulators with oral efficacy against cognitive deficits in Alzheimer's disease model mice, *Bioorg Med Chem* 2020;28:115455.
10. Zhang XZ, Qian SS, Zhang YJ, Wang RQ. *Salvia miltiorrhiza*: A source for anti-Alzheimer's disease drugs. *Pharm Biol* 2016; 54:18-24.
  11. Jiang WY, Jeon BH, Kim YC, Lee SH, Sohn DH, Seo GS. PF2401-SF, standardized fraction of *Salvia miltiorrhiza* shows anti-inflammatory activity in macrophages and acute arthritis in vivo. *IntImmunopharmacol* 2013; 16:160-164.
  12. Huimin Yu LY, Hongzu Zhou, SichangQu, XianghaiZeng, Delong Zhou, Yulian Zhou, Xinglin Li, Zhicheng Liu. Neuroprotection against A $\beta$ 25-35-induced apoptosis by *Salvia miltiorrhiza* extract in SH-SY5Y cells. *NeurochemInt* 2014; 75:89-95.
  13. Wang Q, Yu X, Patal K, Hu R, Chuang S, Zhang G, et al. Tanshinones inhibit amyloid aggregation by amyloid-beta peptide, disaggregate amyloid fibrils, and protect cultured cells. *ACS ChemNeurosci* 2013; 4:1004-1015.
  14. ZeinabBreijyeh, Rafickkaraman. Comprehensive Review on Alzheimer's Disease: Causes and Treatment. *Molecules* 2020, 25(24), 5789.
  15. Yiannopoulou, K.G.; Papageorgiou, S.G. Current and future treatments in alzheimer disease: An update. *J. Cent. Nerv. Syst. Dis.* 2020, 12.
  16. Livingston, G.; Huntley, J.; Sommerlad, A.; Ames, D.; Ballard, C.; Banerjee, S.; Brayne, C.; Burns, A.; Cohen-Mansfield, J.; Cooper, C.; et al. Dementia prevention, intervention, and care: report of the Lancet Commission. *Lancet* 2020, 396, 413–446.
  17. Man Y, Yang L, Zhang D, Bi Y. Cryptotanshinone inhibits lung tumor growth by increasing CD4+ T cell cytotoxicity through activation of the JAK2/STAT4 pathway. *OncolLett* 2016; 12:4094-4098.
  18. VanDyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer's disease. *N Engl J Med.* 2023; 388:9–21.
  19. The Lancet. Lecanemab for Alzheimer's disease: tempering hype and hope. *Lancet.* 2022; 400:1899.
  20. Stefaniak O, Dobrzyńska M, Drzymała-Czyż S, Przysławski J. Diet in the prevention of Alzheimer's disease: current knowledge and future research requirements. *Nutrients.* 2022; 14:4564.

21. Golde TE. Disease-modifying therapies for Alzheimer's disease: more questions than answers. *Neurotherapeutics*. 2022; 19:209–27.
22. Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, et al. Two randomized phase 3 studies of Aducanumab in early Alzheimer's disease. *J PrevAlzheimers Dis*. 2022; 9:197–210.
23. Dubois B, Villain N, Frisoni GB, Rabinovici GD, Sabbagh M, Cappa S, et al. Clinical diagnosis of Alzheimer's disease: recommendations of the international working group. *Lancet Neurol*. 2021; 20:484–96.
24. Morris JK, Vidoni ED, Johnson DK, Van Sciver A, Mahnken JD, Honea RA, et al. Aerobic exercise for Alzheimer's disease: a randomized controlled pilot trial. *PLoS One*. 2017; 12:e0170547.
25. Walker KA, Ficek BN, Westbrook R. Understanding the role of systemic inflammation in Alzheimer's disease. *ACS ChemNeurosci* 2019; 10:3340-3342.
26. Cai R, Wang LN, Fan JJ, Geng SQ, Liu YM. New 4-N-phenylaminoquinoline derivatives as anti-oxidant, metal chelating and cholinesterase inhibitors for Alzheimer's disease. *BioorgChem* 2019; 93: 1-24.
27. Loera-Valencia R, Cedazo-Minguez A, Kenigsberg PA, Page G, Duarte AI, Giusti P, et al. Current and emerging avenues for Alzheimer's disease drug targets. *J Int Med* 2019; 286:398- 437.
28. Kabir MT, Uddin MS, Begum MM, Thangapandiyam S, Rahman MS, Aleya L, et al. Cholinesterase inhibitors for Alzheimer disease: Multitargeting strategy based on anti-Alzheimer's drugs repositioning. *Curr Pharm Des* 2019, 25:3519-3535.
29. Kabir MT, Abu Sufian M, Uddin MS, Begum MM, Akhter S, Islam A, et al. NMDA receptor antagonists: Repositioning of memantine as multitargeting agent for Alzheimer's therapy. *Curr Pharm Des* 2019; 25: 3506-3518.
30. Mandal PK, Shukla D, Tripathi M, Ersland L. Cognitive improvement with glutathione supplement in Alzheimer's disease: A way forward. *J Alzheimers Dis* 2019; 68:531-535.
31. Deardorff WJ, Grossberg GT. Targeting neuroinflammation in Alzheimer's disease: evidence for NSAIDs and novel therapeutics. *Expert Rev Neurother* 2017; 17:17-32.

32. Soheili M, Khalaji F, Mirhashemi M, Salami M. The effect of essential oil of *Lavandulaangustifolia* on amyloid beta polymerization: An in vitro study. *IJCCE* 2018; 37:201-207
33. Zeng Q, Siu W, Li L, Jin Y, Liang S, Cao M, et al. Autophagy in Alzheimer's disease and promising modulatory effects of herbal medicine. *ExpGerontol* 2019; 119:100-110.
34. Soheili M, Rezaei M, Salami M. Anti-acetylcholine esterase activity of aqueous extract of *lavandulaangustifolia* and its toxicity effect on HepG2 cell line. *Koomesh* 2017; 19:263-268.
35. Soheili M, Salami M. *Lavandulaangustifolia* biological characteristics: An in vitro study. *J Cell Physiol* 2019:1-7.
36. Watson K, Hatcher D, Good A. A randomised controlled trial of Lavender (*LavandulaAngustifolia*) and Lemon Balm (*Melissa Officinalis*) essential oils for the treatment of agitated behaviour in older people with and without dementia. *Complement Ther Med* 2019; 42:366-373.
37. Zhao, J.; Liu, X.; Xia, W.; Zhang, Y.; Wang, C. Targeting amyloidogenic processing of APP in Alzheimer's disease. *Front. Mol. Neurosci.* 2020, 13, 137
38. Zhipei sang, Ling haung. Alzheimer's disease therapeutics: current strategies and future directions .*Privileged Scaffolds in Drug Discovery*; 2023:405-473
39. Alzheimer's disease: Updated multi-targets therapeutics are in clinical and in progress, *European Journal of Medicinal Chemistry.* 2022; 238, 114464.
40. Anuradhasharma, Poolampiplani. Acridine: A Scaffold for the Development of Drugs for Alzheimer's Disease. *Current Topics in Medicinal Chemistry.* 2023: 23(13).
41. Oskouie AA, Yekta RF, Tavirani MR, Kashani MS, Goshadrou F. *Lavandulaangustifolia* effects on rat models of Alzheimer's disease through the investigation of serum metabolic features using NMR metabolomics. *Avicenna J Med Biotechnol* 2018; 10:83-92.